The purpose of this study is to compare the efficacy and safety of pitavastatin with that of atorvastatin in patients with type II diabetes mellitus (type II DM) and combined dyslipidemia.
Study Type
INTERVENTIONAL
Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
QUADRUPLE
Enrollment
418
Pitavastatin 4 mg QD
Atorvastatin 20 mg
Percent Change From Baseline Low Density Lipoprotein Cholesterol (LDL-C)
Percent change from baseline to Week 12 low density lipoprotein cholesterol (LDL-C)
Time frame: 12 weeks
Number of Patients Attaining National Cholesterol Education Program (NCEP) LDL-C Target
Number of patients attaining National Cholesterol Education Program (NCEP)LDL-C target (LDL-C less than 160 mg/dL) at 12 weeks
Time frame: 12 weeks
This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.
CCBR Aalborg
Aalborg, Denmark
CCBR A/S
Ballerup Municipality, Denmark
CCBR Vejle
Vejle, Denmark
Gemeinschaftspraxis am Bahnhof
Berlin-Spandau, Germany
Pharmakologisches Studienzentum Chemnitz
Chemnitz, Germany
Internistische Diabetische Schwerpunktpraxis Dr.
Frankfurt am Main, Germany
Internistische Gemeinschaftspraxis
Mainz, Germany
Gemeinschaftspraxis Dr. Senftleber, Dr. Kohler
Messkirch, Germany
Bhagwan Mahaveer Jain Heart Centre
Bangalore, India
Sri Ramachandra Medical College Hospital
Chennai, India
...and 25 more locations